Loading…
Scilex Holding Company is projected to rise to $6.83 by 2027, a +4% move from its current price of $6.56. SCLX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.21 | $6.56 | $6.94 | +0.05% |
| Aug 6 | $6.07 | $6.57 | $7.11 | +0.10% |
| Aug 7 | $5.97 | $6.57 | $7.24 | +0.15% |
| Aug 8 | $5.88 | $6.57 | $7.35 | +0.20% |
| Aug 9 | $5.81 | $6.58 | $7.45 | +0.25% |
| Aug 10 | $5.74 | $6.58 | $7.54 | +0.30% |
| Aug 11 | $5.68 | $6.58 | $7.63 | +0.36% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.68 | $6.58 | $7.63 | +0.36% |
| Week 2 | $5.36 | $6.61 | $8.14 | +0.71% |
| Week 3 | $5.14 | $6.63 | $8.56 | +1.07% |
| Week 4 | $4.95 | $6.65 | $8.94 | +1.43% |
| Week 5 | $4.80 | $6.68 | $9.29 | +1.79% |
| Week 6 | $4.67 | $6.70 | $9.62 | +2.15% |
| Week 7 | $4.55 | $6.72 | $9.93 | +2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scilex Holding Company is a healthcare company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), SP-103 (lidocaine topical system) 5.4%, and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), which address various pain indications. It has agreements with Oishi and Itochu to develop lidocaine tape products, Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA, and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Scilex Holding Company (SCLX) is a healthcare stock currently trading at $7.03 per share with a market cap of $49.44M and a rank of 4380.
The price outlook shows a near-term path around the current level, with longer-term upside suggested by the forecast. The 2026 average price is $7.03, followed by 2027 at $6.86 and 2028 at $7.21, indicating a mixed near-term trajectory.
From 2029 onward, the forecast turns bullish, with 2029 average $11.63, 2030 $12.48, 2031 $12.87, 2032 $13.22, 2033 $11.01, 2034 $13.00, 2035 $15.02, 2040 $19.48, and 2050 $51.96 as the average prices. The maximums rise accordingly, up to $21.63 (2030), $23.10 (2031), $24.47 (2032), $20.94 (2033), $25.36 (2034), $29.98 (2035), $42.74 (2040), and $119.51 (2050). The long-run ROI peaks at 639.1% by 2050, with bullish sentiment across the later years.
A major floor 33.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 51.4% above — a clean break opens room to run.
A major ceiling 70.0% above — clearing it would confirm fresh momentum.
Key SCLX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCLX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.74 | Sell | $6.77 | Sell |
| MA 10 | $7.04 | Sell | $7.11 | Sell |
| MA 20 | $8.04 | Sell | $7.49 | Sell |
| MA 50 | $7.59 | Sell | $7.68 | Sell |
| MA 100 | $7.53 | Sell | $8.23 | Sell |
| MA 200 | $10.59 | Sell | $10.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.63 | Neutral |
| Stoch RSI (14) | 6.16 | Buy |
| CCI (20) | -91.71 | Neutral |
| Williams %R (14) | -96.05 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | -27.71 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 3.95 | Buy |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -1.02 | Sell |
| Ultimate (7,14,28) | 36.29 | Neutral |
| Momentum (10) | -1.77 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 6.47 | Buy |
| ADX (14) | 14.81 | Neutral |
| ATR (14) | 0.38 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 40. The SMA50 is $6.20 and the SMA200 is $7.18. The stock has a 30-day range between $4.58 and $10.80, reflecting a broad trading band.
Support is at $4.38 and resistance at $9.93, forming a price envelope around the current level for the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.69 | $6.56 | $9.99 | 0% | Neutral | |
| $4.98 | $6.83 | $10.13 | +4% | Neutral | |
| $4.85 | $7.09 | $11.21 | +8% | Neutral | |
| $7.68 | $11.81 | $19.64 | +80% | Bullish | |
| $7.96 | $12.84 | $22.24 | +96% | Bullish | |
| $7.76 | $13.08 | $23.45 | +99% | Bullish | |
| $7.82 | $13.75 | $25.42 | +110% | Bullish | |
| $6.38 | $11.68 | $22.20 | +78% | Bullish | |
| $7.13 | $13.59 | $26.48 | +107% | Bullish | |
| $8.40 | $16.63 | $33.18 | +154% | Bullish | |
| $9.36 | $20.81 | $45.63 | +217% | Bullish | |
| $27.11 | $60.25 | $138.57 | +818% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.69 | $6.56 | $8.65 | +0.00% |
| September 2026 | $5.88 | $7.15 | $9.07 | +8.97% |
| October 2026 | $5.57 | $6.87 | $8.89 | -3.89% |
| November 2026 | $5.69 | $7.10 | $9.33 | +3.31% |
| December 2026 | $5.95 | $7.49 | $9.99 | +5.53% |
Click any year to see its month-by-month SCLX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Scilex Holding Company's 2026 outlook centres on $6.56, within a $3.69 to $9.99 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SCLX could reach as high as $10.13, with a base case around $6.83 and support toward $4.98 — roughly +4% from $6.56. Price action looks broadly range-bound.
Expect SCLX to range from $4.85 to $11.21 through 2028. The $7.09 average target implies a +8% move from current prices. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
The SCLX price prediction for 2029 points to an average of $11.81 (low $7.68, high $19.64) — a potential gain of +80% on today's $6.56. Momentum favours further upside here.
In 2030, SCLX is projected to trade between $7.96 and $22.24, averaging $12.84 — a potential gain of +96% from today's $6.56. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Scilex Holding Company's 2031 outlook centres on $13.08, within a $7.76 to $23.45 range. That is up +2% on the projected 2030 average. That marks a +99% change versus current levels. Momentum favours further upside here.
By 2032, SCLX could reach as high as $25.42, with a base case around $13.75 and support toward $7.82 — roughly +110% from $6.56. Buyers look set to stay in control over this stretch.
Expect SCLX to range from $6.38 to $22.20 through 2033. The $11.68 average target implies a +78% move from current prices. That is -15% versus the projected 2032 average. Momentum favours further upside here.
The SCLX price prediction for 2034 points to an average of $13.59 (low $7.13, high $26.48) — a potential gain of +107% on today's $6.56. Buyers look set to stay in control over this stretch.
In 2035, SCLX is projected to trade between $8.40 and $33.18, averaging $16.63 — a potential gain of +154% from today's $6.56. That is up +22% on the projected 2034 average. Momentum favours further upside here.
Scilex Holding Company's 2040 outlook centres on $20.81, within a $9.36 to $45.63 range. That is up +25% on the projected 2035 average. That marks a +217% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SCLX could reach as high as $138.57, with a base case around $60.25 and support toward $27.11 — roughly +818% from $6.56. Momentum favours further upside here.
Investing $1,000 in SCLX today (≈ 152.439024 SCLX) could be worth
$9,184.33
+$8,184.33 (+818%) by 2050 · US Dollar
Based on the average projected SCLX price of $60.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCLXwould be worth at today's price.
$1,000 invested in SCLX on Jul 31, 2025 (≈ 74.515648 SCLX) would be worth
$488.82
-$511.18 (-51.1%) today · 0.49× · US Dollar
Based on a SCLX entry price of $13.42 vs. today's $6.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.84 | $959.06 | -4.1% |
| 1 month ago | $7.88 | $832.49 | -16.8% |
| 3 months ago | $10.58 | $620.04 | -38.0% |
| 6 months ago | $9.14 | $717.72 | -28.2% |
| 1 year ago | $13.42 | $488.82 | -51.1% |
| All time (5.0y) ago | $348.25 | $18.84 | -98.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCLX forecast.
Our base-case forecast reaches $13.00 around 2031.
Implied market cap at $13.00: $91.43M
In the multi-year view, the outlook shifts to a bullish stance beginning in 2029, with the average price rising from $11.63 in 2029 to $12.48 in 2030 and continuing upward through the mid-2020s and beyond. The forecast shows a sustained upside, with 2031 ($12.87), 2032 ($13.22), and 2035 ($15.02) all delivering higher averages and strong ROIs (83.1% in 2031, 88.1% in 2032, and 113.6% in 2035).
The trajectory extends to 2040 with an average of $19.48 and ROI of 177.1%, and reaches a long-run average of $51.96 with a maximum of $119.51 in 2050, yielding a ROI of 639.1% and a bullish sentiment. These figures illustrate meaningful long-term upside but are estimates and subject to uncertainty and market factors; actual results may differ from the projections.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $12.48, with a minimum of $7.72 and a maximum of $21.63, and an estimated ROI of 77.5% with a bullish sentiment.
Near term shows mixed results with a neutral stance in 2026–2028, but the long-term forecast is bullish from 2029 onward, with higher average prices and ROI culminating in a 2050 average of $51.96 and a max of $119.51, ROI 639.1%. These are estimates and not guarantees.
The forecast maximum for 2050 is $119.51, which exceeds $100, indicating a theoretical potential to reach that level over the long term, but it is not guaranteed.
The 30-day range is $4.58 to $10.80. RSI(14) is 40, indicating neutral momentum, with a 50-day average of $6.20 and a 200-day average of $7.18. Support is at $4.38 and resistance at $9.93.
Current price is $7.03 per share, with a market cap of $49.44M and a rank of 4380.
Scilex Holding Company Community Discussion
0Share your Scilex Holding Company price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.